Inhibrx Biosciences, Inc. (INBX NASDAQ) stock market data APIs
$88.9404
-0.08(-0.1%)
as of December 5, 2025
Try our APIs with
free plan!
Inhibrx Biosciences, Inc. Financial Data Overview
Price chart is built with
Anychart
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Prev. Close
88.9404
Open
88.8641
High
91.3781
Low
85.7492
52 wk Range
10.805-90.58
Market Cap
487 M
Shares Outstanding
14 485 K
Revenue
1 400 K
EPS
-2.28
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Inhibrx Biosciences, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Inhibrx Biosciences, Inc. data using free add-ons & libraries
Get Inhibrx Biosciences, Inc. Fundamental Data
Inhibrx Biosciences, Inc. Fundamental data includes:
- Net Revenue: 1 400 K
- EBITDA: -96 169 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-14
- EPS/Forecast: -1.57
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Inhibrx Biosciences, Inc. News
New
INBX Advances Ozekibart Program, Plans BLA Submission For Chondrosarcoma In Q2 2026
(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical company, reported its third-quarter 2025 financial results and highlighted the upcoming events to watch in the coming m...
Inhibrx Reports Third Quarter 2025 Financial Results
SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion ...
LGND: Target Up On Improved Growth Outlook
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported outstanding results for its third quarter, with revenues almost double o...
Biotech Stocks Hit 52-Week Highs: MTSR, INSM, ABVX, MAZE Lead October 30 Surge
(RTTNews) - Risk runs high, but so does the upside. Biotech investing thrives on bold bets and breakthrough data. On October 30, 2025, a wave of clinical-stage and commercial biopharma stocks surged t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
